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Abstract 
 
The emergence of drug resistance limits the efficacy of targeted therapies 
in human tumors. The prevalent view is that resistance is a fait accompli: 
when treatment is initiated, cancers already contain drug-resistant mutant 
cells. Bacteria exposed to antibiotics transiently increase their mutation 
rates (adaptive mutability), thus improving the likelihood of survival. We 
investigated  whether human colorectal cancer (CRC) cells likewise exploit 
adaptive mutability to evade therapeutic pressure. We found that 
epidermal growth factor receptor (EGFR)/BRAF inhibition down-regulates 
mismatch repair (MMR) and homologous recombination (HR) DNA repair 
genes, and concomitantly up-regulates error-prone polymerases in drug-
tolerant (persister) cells. MMR proteins were also down-regulated in 
patient-derived xenografts and tumor specimens during therapy. 
EGFR/BRAF inhibition induced DNA damage, increased mutability and 
triggered microsatellite instability. Thus, like unicellular organisms, tumor 
cells evade therapeutic pressures by enhancing mutability. 
 
 
 
 
 
Over 75 years ago, Luria and Delbrück demonstrated that bacterial resistance to 
phage viruses was due to random mutations that spontaneously occurred in the 
absence of selection (1). Resistance to targeted therapies in human tumors is 
also widely thought to be due to mutations that exist prior to treatment (2). The 
conventional view is that relapses occur because drug-resistant mutant 
subclones are present in any detectable metastatic lesion prior to initiation of 
therapy. According to this view, resistance is a ‘fait accompli’, and the time to 
recurrence is merely the interval required for pre-existing drug resistant 
(mutant) cells to repopulate the lesion (3).   
 
Here we explore the hypothesis that resistance to targeted therapies can also be 
fostered by a transient increase in genomic instability during treatment, leading 
to de novo mutagenesis. A similar process has been shown to increase the 
emergence of microbial strains resistant to antibiotics (4, 5). In a stable 
microenvironment, the mutation rate of microorganisms is usually low, which 
precludes the accumulation of deleterious mutations. However, several 
mechanisms of stress-induced genetic instability and increased mutability, 
known as stress-induced mutagenesis (SIM), have been described in bacteria and 
yeast (6-12).  
 
Bacterial persister cells can survive lethal stress conditions imposed by 
antibiotics through a reduction in growth rate. A subsequent  reduction in the 
efficiency of DNA mismatch repair (MMR) (4, 9, 13), and a shift to error-prone 
DNA polymerases increases the rate at which adaptive mutations occur in the 
surviving population (4, 9, 14, 15). Selection then allows the growth of mutant 
subpopulations capable of replicating under stressful conditions. Once the 
stressed population has adapted to the new conditions, the hypermutator status 
is counter-selected to avoid accumulation of deleterious mutations and to 
prevent the continuous increase of mutational load (9, 16-20).  Together, these 
processes boost genetic diversity, foster adaptability to new microenvironments 
and contribute to the development of resistance (9, 12, 18, 19).  
 
In the setting of cancer, the emergence of a drug tolerant  persister  population is 
often observed when oncogene-dependent tumor cells are challenged with 
targeted agents (21). Persister cancer cells survive exposure to targeted 
therapies through poorly understood mechanisms (21), and represent a 
reservoir from which genetically divergent, drug-resistant derivatives eventually 
emerge (22, 23). Recent work showed that drug-resistant mutant cancer cells can  
originate not only from rare, pre-existing mutant clones, but also from drug-
tolerant sub-populations (24). The probability that the latter resistance 
mechanism occurs would be greatly increased if the genetic diversity of tumor 
cells was enhanced during treatment. Accordingly, we hypothesized that during 
the persister state tumor cells, like unicellular organisms, alter DNA repair and 
replication mechanisms to enhance adaptive mutability. 
 
Targeted therapy-induced  down-modulation of MMR and HR proficiency of 
CRC cells. 
 
To test our hypothesis, we studied the response of microsatellite stable (MSS) 
human colorectal cancer (CRC) cell lines  to the anti-EGFR (epidermal growth 
factor receptor) antibody cetuximab, which is approved, together with 
panitumumab, for treatment of patients with metastatic CRC whose tumors lack 
RAS and BRAF mutations (25); or with BRAF inhibitor dabrafenib as 
combinatorial treatment, which has shown promising activity in patients with 
CRC harboring BRAF mutations (26). We selected human CRC cell lines that are 
RAS and BRAF wild-type and sensitive to EGFR blockade (DiFi cells, fig. S1A), or 
that carry the oncogenic BRAF p.V600E mutation and are sensitive to 
concomitant EGFR and BRAF inhibition (WiDr cells, fig. S1A). Treatment with 
targeted agents led to G1 cell cycle arrest (fig. S1B). However, a small number of 
drug-tolerant persister cells survived several weeks after treatment initiation 
(fig. S1, C and D). Indeed, when drug pressure was removed, these cells rapidly 
resumed growth and again showed sensitivity to targeted therapy, thus 
demonstrating that persisters are only transiently and reversibly resistant to the 
treatment (fig. S1, E and F). In contrast, prolonged treatment led to the 
generation of permanently resistant cells, which did not re-acquire sensitivity 
after removal of drug pressure (fig. S1, E and F). 
 
We next assessed whether CRC cells modulate the expression of DNA repair 
genes upon drug treatment. Transcriptional profiles revealed decreased 
expression of the MMR genes MLH1, MSH2, MSH6, as well as homologous 
recombination (HR) effectors, such as BRCA2 and RAD51 (Fig. 1A, fig. S1, G and 
H). Expression of EXO1, a gene coding for an exonuclease that participates in 
mismatch and double-strand break (DSB) repair, was also affected (Fig. 1A, fig. 
S1, G and H). A time-dependent down-regulation of MMR and HR proteins was 
also observed (Fig. 1B, fig. S2, A and B). Comparable results were obtained in 
another cetuximab-sensitive human CRC cell line, NCIH508 (fig. S3, A to C), and 
in BRAF-mutant HT29 cells that were derived from the same patient from whom 
the WiDr cell line originated (fig. S3, D and E). Furthermore, we confirmed that 
down-regulation or loss of DNA repair components is maintained in persister 
cells (fig. S4, A to D). Therapy-induced modulation of DNA repair genes 
expression was transient and expression levels returned to normal upon 
removal of treatment (fig. S5A). Cancer cells that had previously developed 
permanent resistance to targeted agents did not modulate expression of DNA 
repair genes in response to drugs (fig. S5, B and C). 
 
To ascertain whether targeted therapies affect DNA repair competence in CRC 
cells, we used fluorescence-based multiplex host cell reactivation (FM-HCR) 
assays (27). CRC cells were transfected with a G:G mismatch-containing plasmid 
to determine the impact of drug treatment on MMR capacity. A MMR deficient 
(MMRd) human CRC cell line (LIM1215) was used as a positive control for MMR 
loss. We found that in CRC cells treated with targeted agents, MMR proficiency 
(MMRp) was reduced to levels comparable to those observed in LIM1215 (Fig. 
1C, fig. S6A). 
 
We next evaluated cellular HR capability by using the two-step, plasmid-based,  
pDRGFP/pCBASce-I assay (28). Upon stable expression of the pDRGFP plasmid, 
we measured the generation of a green fluorescent signal upon DSBs induced by 
Sce-I expression. By this assay, both DiFi and WiDr cells showed a marked 
reduction in HR proficiency upon treatment with targeted therapies (Fig.1D, fig. 
S6B).  
 
MMR proteins are down-regulated in samples of CRC residual disease after 
targeted treatment. 
 
To determine whether the cell-based findings extend to patient-derived tumor 
samples, we exploited our CRC biobank of molecularly and therapeutically 
annotated patient-derived xenograft (PDX) models (29, 30). We selected six MSS 
PDX models with wild-type KRAS, NRAS and BRAF in which EGFR inhibition by 
cetuximab led to tumor regression to a variable extent, paralleling the clinical 
scenario (Fig. 2A). Immunohistochemistry analysis unveiled areas with down-
regulation of MLH1 and/or MSH2 in all neoplastic samples obtained when 
tumors were at the point of maximum response to cetuximab, but still contained 
residual persisters (Fig. 2B and C, fig. S7, A to D), as compared with placebo-
treated controls.  
 
We next investigated whether down-regulation of DNA repair proteins also 
occurs in clinical specimens from two CRC patients who achieved an objective 
partial response upon treatment with FOLFOX plus panitumumab. In both 
instances, tumor specimens were longitudinally collected at diagnosis and at 
maximal therapeutic response, when a limited number of tumor cells persist 
despite treatment. MLH1 and MSH2 were down-regulated in tumor samples 
obtained at response compared to pre-treatment specimens, confirming the 
clinical relevance of our findings (Fig. 2D). 
 
Induction of DNA damage and error-prone DNA polymerases in CRC cells 
treated with targeted therapies. 
 
In addition to reduced DNA repair ability, we found that targeted therapies 
triggered a switch from high-fidelity to low-fidelity DNA polymerases. DNA 
polymerases usually involved in accurate DNA replication, such as POLδ and 
POLε were down-regulated; whereas DNA polymerases characterized by poor 
accuracy, low processivity and absence of proofreading capacity (i.e., error-
prone polymerases) were induced (Fig. 1A, fig. S4A). These included Polι, Polκ, 
and Rev1 (which belong to Y family polymerases, orthologous to the bacterial 
stress-induced polymerases Pol IV and Pol V), as well as Polλ and Polµ, (31) (Fig. 
1 A and B; figs S1, G and H; S2B; S3, B to C and E; S4, A and D). Error-prone 
polymerases replace canonical high-fidelity polymerases that stall when 
encountering a DNA lesion, and facilitate DNA replication across DNA damage 
sites in a manner that introduces errors into the genome (15, 16, 20); this may 
lead to bases mispairings, incorporation of aberrant DNA primer ends, and 
increased mutagenesis rate (32, 33). 
 
We therefore investigated whether treatment with targeted therapies leads to 
genomic damage in cancer cells, and if error-prone mediated repair of DNA 
damage was favored when CRC cells encountered the hostile environment 
imposed by targeted therapies. Indeed, quantification of phosphorylation of 
H2AX at Ser 139 (γH2AX), a common marker of DNA damage (34), revealed a 
dose- and time-dependent increase in the number of foci-positive nuclei upon 
drug treatment (Fig. 3 A and B, fig. S8, A and B), while no further increase was 
observed in permanently resistant cells upon drug treatment (fig. S8, C and D). In 
addition, we observed a dose- and time-dependent increase in the number of 
53BP1-positive nuclei upon EGFR and BRAF blockade (fig. S9, A and B). In direct 
opposition to BRCA1, 53BP1 promotes non-homologous end joining (NHEJ)-
mediated DSB repair while preventing HR through restriction of end resection 
(35). These data suggest that targeted therapies trigger a switch from high-
fidelity to error-prone mediated repair of DNA damage, thereby potentially 
increasing the occurrence of mutations conferring drug resistance.  
 
We next explored the possible causes of the DNA damage observed upon 
targeted therapies administration. While several chemotherapeutic agents 
directly generate DNA damage, drugs interfering with oncogenic signaling (such 
as EGFR or BRAF inhibitors) are not directly genotoxic. Intriguingly, however, it 
has been shown that certain targeted therapies,  such as ABL and BRAF 
inhibitors, increase the levels of reactive oxygen species (ROS) in cancer cells 
(36, 37), potentially contributing to DNA damage during treatment. ROS levels 
significantly increased when CRC cells were exposed to EGFR and BRAF 
inhibitors (Fig. 3C). In contrast, ROS levels were not increased in permanently 
drug-resistant (adapted) cells upon drug treatment (fig. S9C).  
 
The drug-induced increase in ROS levels was abrogated when targeted therapies 
were administered in the presence of the antioxidant N-acetyl-L-cysteine (NAC) 
(Fig. 3C). NAC administration partially reduced the number of γH2AX foci-
positive nuclei upon EGFR and BRAF blockade (fig. S10, A and B). However, co-
treatment with NAC did not prevent or rescue down-regulation of DNA repair 
genes (fig. S10C). Notably, addition of NAC delayed onset of relapse to targeted 
therapies when administered together with MAPK pathway inhibitors (fig. S10, D 
and E)(38, 39). 
 
Interfering with oncogenic dependencies initiates stress response in CRCs. 
 
To elucidate the mechanistic basis of therapy-induced mutagenesis in cancer 
cells, we tested whether the adaptive mutability that we observed in response to 
targeted therapies was simply a secondary response to G1 cell cycle arrest or 
DNA damage, or whether it represented an active stress-response. We found that 
thymidine-mediated cell cycle stress (fig. S11, A to C) or direct DNA damage with 
the alkylating agent oxaliplatin (fig. S11, D to F) rather promoted up-regulation 
of the MMR and HR repair systems (fig. S11C and F); while G1 cell cycle arrest by 
nutrient starvation did not lead to modulation of DNA repair gene expression 
(fig. S11, G to I). In bacterial cells, both the DNA damage-activated SOS response 
and the general stress response appear to be required to induce adaptive 
mutagenesis (14). We therefore examined the modulation of the kinase 
mammalian target of rapamycin (mTOR), which is a master regulator of 
mammalian cellular stress response (40). Indeed, the mTOR effectors pS6K–
p70K were down-regulated with kinetics comparable to that of MMR and HR 
modulation, upon EGFR and BRAF pharmacological blockade (Fig. 3D). However, 
silencing of mTOR did not affect expression of DNA repair proteins or γH2AX 
(Fig. 3E). It is therefore plausible that down-regulation of mTOR contributes to 
stress-induced mutagenesis of cancer cells but is not sufficient to activate this 
phenotype. 
 
The exquisite sensitivity of DiFi and WiDr cells to EGFR and BRAF blockade 
reflects cell-specific oncogenic alterations. The EGFR locus is amplified in DiFi 
cells (2); the WiDr cells carry the BRAF p.V600E oncogenic mutation, but they 
also become dependent on feedback activation of EGFR when treated with BRAF 
inhibitors (41). We therefore assessed whether interfering with the oncogenic 
dependency of cancer cells could directly initiate the drug-induced stress 
phenotype. Indeed, siRNA-mediated knock-down of EGFR or KRAS in DiFi cells, 
and BRAF (+/- EGFR) in WiDr cells led to reduced expression of DNA repair 
proteins, triggered DNA damage and mTOR down-modulation (Fig. 3E), and 
increased ROS levels (fig. S12). These results exclude the possibility that drug-
induced down-modulation of DNA repair pathways could be due to a nonspecific 
(off-target) effect of the anti-EGFR antibody cetuximab or the BRAF inhibitor 
dabrafenib. 
 
Targeted therapies induce adaptive mutability in CRC cells. 
 
Next, we tested whether the stress response induced by targeted therapies 
translated into increased mutagenesis in CRC cells. We used a reporter assay in 
which a dinucleotide CA-repeat microsatellite drives the NanoLuc enzyme 
coding sequence out-of-frame (Fig. 4A). Random mutations that introduce 
frameshifts in this region, in absence of a functional MMR, would restore the 
NanoLuc open reading frame leading to bioluminescence. Analogous approaches 
have previously been used to measure MMR defects in cancer cells (42-44). To 
validate the assay, we first introduced the CA-NanoLuc vector into a MMRd 
human CRC cell line (HCT116) and three MMRp human CRC cell lines (DiFi, 
WiDr, NCIH508). The NanoLuc signal was significantly higher in MMRd cells 
after 48 hours of standard growth conditions (Fig. 4B). This difference was 
further increased when HCT116 were kept in culture for several days, while the 
signal in the MMRp lines remained low (Fig. 4B), indicating that the CA-NanoLuc 
assay effectively detects MMR deficiency in cancer cells.  
We next used the CA-NanoLuc system to measure the impact of ectopic 
inactivation of MMR in CRC cells. To this end, we used CRISPR-CAS9 to inactivate 
the MLH1 gene in HT29 human CRC cell line. After the isolation of two 
independent MLH1 knock-out (KO) clones (fig. S13, A and B), they were 
transduced with the CA-NanoLuc vector. MLH1 KO clones exhibited higher levels 
of NanoLuc signal as expected, confirming that the assay can detect inactivation 
of DNA MMR (Fig. 4C). Next, drug-dependent (transient) MMR down-regulation 
was evaluated. EGFR and BRAF inhibition led to time-dependent increases of 
bioluminescence (Fig. 4D), paralleling the down-regulation of DNA repair 
effectors and up-regulation of low-fidelity polymerases. We further found that 
permanently resistant derivatives no longer exhibited adaptive mutability in 
response to targeted therapies (fig. S14). 
 
Genomic alterations in CRC cells upon treatment with targeted therapies.  
 
To determine whether molecular evidence of adaptive mutability was present in 
the genome of CRC cells treated with EGFR and BRAF inhibitors, we analyzed 
whole-exome sequencing (WES) data from DiFi and WiDr parental,  persister, 
and drug-resistant derivative cells. The overall mutational burden (number of 
mutations/megabase) of persisters, and drug resistant cell population was only 
marginally affected (fig. S15, A and B). As a control, we assessed whether MMR 
permanent inactivation, induced by MLH1 KO, affected the mutational burden of 
HT29 CRC cells, and found that it was only marginally affected (fig. S16A). 
We therefore changed approach. Since treatment with targeted therapies led to a 
transient MMR deficient phenotype, we reasoned that MMR status could be more 
easily detected by examining microsatellite regions, where DNA replication 
slippage errors occur frequently and are ineffectively repaired in the absence of 
MMR. Indeed, WES analysis unveiled alterations in microsatellite regions of 
HT29 in which the MLH1 gene was genetically knocked-out (fig. S16, B and C).  
Importantly, we also detected increased genetic instability in the microsatellite 
regions of CRC cells made resistant to targeted agents (Fig. 5, A and B), as shown 
by a shift in the length of microsatellite regions, highlighting the impact of 
targeted therapies on DNA repair process and mutagenicity. To detect the 
occurrence of microsatellite alterations in non-clonal cell populations, we 
utilized a high depth capture panel that detects hotspot somatic variants as well 
as shifts in length of microsatellite regions. Indeed, such high sensitivity analysis 
unveiled a significant shift in the length of microsatellite regions in both 
persister and drug-resistant cells (Fig. 5 C, fig. S17).   
 
We next assessed the impact of targeted therapies on the genomic landscape of 
PDXs. To do this, we studied a PDX (CRC0078) (Fig. 2A, fig. S7D) that was 
continuously treated with cetuximab until it developed resistance (fig. S18). WES 
analysis of the cetuximab-resistant tumor tissue revealed alterations in 
microsatellite genomic regions which were not present in the PDX tumor 
collected from the corresponding untreated mouse (Fig. 5, D and E). Overall, 
these results indicate that CRC cells and a CRC PDX exposed to targeted therapies 
experience loss of replication fidelity in regions of nucleotide repeats. 
 
 
Discussion 
 
The development of resistance has emerged as a major limitation of targeted 
therapies directed against oncoproteins, such as EGFR, BRAF and ABL (25).  
 
In this study, we tested the hypothesis that cancer cells treated with targeted 
therapies activate stress-induced mutagenic mechanisms. We found that 
persister (drug-tolerant) cancer cells that survive EGFR and/or BRAF inhibition 
exhibit DNA damage, down-regulate mismatch and homologous recombination 
repair proteins, switch from high-fidelity to error-prone DNA repair, and 
transiently increase their mutagenic ability.  
 
Stress-induced mutagenesis is a characteristic trait of unicellular organisms to 
transiently accelerate genetic diversity, in a fraction of the population, when 
encountering a hostile environment. (16). Indeed, we found that therapy-induced 
modulation of DNA repair in cancer cells is also transitory and reverts back once 
a mutational landscape able to restore the ability to grow in the presence of the 
drug is achieved. We postulate that in cells of multicellular organisms, stress-
induced mutagenesis is not operational. However, in cancer cells that have lost 
tissue-imposed homeostasis, and in many ways operate like unicellular 
organisms, this ancestral program is still available and is unleashed by 
oncoprotein-targeted drugs. A similar process has also been observed in cancer 
cells undergoing hypoxia-driven stress (7, 45, 46). 
 
The analysis of mutational signatures has emerged as a valuable tool to 
document the mutational processes operative in cells (47). In future studies, it 
will be interesting to establish whether specific mutational signatures emerge 
under targeted therapies. Resolving such processes, which we postulate occur 
transiently in small cell subpopulations, is likely to require extensive genomic 
comparisons of multiple clones and independent datapoints. 
 
These results may have clinical implications. The knowledge that cancer cells 
under therapeutic stress down-regulate key effectors of the DNA repair 
machinery, such as MMR and HR, exposes a vulnerability that could be clinically 
exploited. For example, it will be important to assess whether  down-regulation 
of HR proteins confers sensitivity to poly-ADP-ribose polymerases (PARP) 
inhibitors as observed in HR deficient cancers (48-50). Moreover, 
pharmacological or genetic interference could be deployed to curb the cellular 
mechanisms that initiate drug-driven adaptive mutagenesis with the goal of 
reducing the generation of new variants during treatment. This strategy could 
potentially increase and prolong the clinical efficacy of targeted therapies. 
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Figure Legends 
 
 
 
 
Fig. 1. CRC cells modulate DNA repair effectors in response to targeted 
agents. (A) CRC cells were treated with cetuximab alone (DiFi) or in 
combination with the BRAF inhibitor dabrafenib (WiDr) for 96h and RNAseq 
analysis was performed. Mismatch repair (MMR) (yellow), homologous 
recombination (HR) (green), and DNA polymerases (blue) genes are reported. 
Results represent means of two independent experiments. (B) CRC cells were 
treated and analyzed at indicated time points by Western blot. (C) CRC cells were 
transfected with G:C undamaged (UNDAMAG) plasmid or with G:G mismatch-
damaged (DAMAG) plasmid. Where indicated (DRUG), cells were treated with 
targeted therapies for fifty-sixty hours and analyzed by flow cytometry. A mock 
transfection was used as control. Quantification of MMR capacity of each cell line 
relative to control is reported in the bar graph. MMR deficient CRC cells LIM1215 
were used as a positive control for MMR loss. Results represent means of two 
independent experiments. *p< 0.05 (Student’s t test). (D) pDRGFP-stably 
expressing CRC cells were transfected with the pCBASce-I plasmid and then 
either left in the absence of drug or treated with targeted therapies for fifty-sixty 
hours and analyzed by flow cytometry. A mock transfection was used as control. 
Quantification of HR capacity of each cell line relative to mock is reported in the 
bar graph. Results represent means ± SD (n=3). ** p< 0.01 (Student’s t test). 
 
Fig. 2. MMR down-regulation in CRC PDXs and patients treated with 
targeted therapies. (A) Extent of tumor regression in PDX models after 
treatment with cetuximab (20 mg/kg twice weekly) for six weeks. Each bar is the 
average of tumor volumes from 6 mice. (B) Growth curve kinetics in two out of 
six PDXs. Mean tumor volumes ± SEM (n=6). Gray arrows, treatment initiation. 
(C) Immunohistochemical staining with anti-MLH1 and anti-MSH2 antibodies of 
histologic tumor sections derived from indicated PDXs treated with cetuximab 
for six weeks. Tumor section derived from placebo arm was used as control. 
Scale bar 0.1mm. Magnifications ×40 (scale bar 0.05mm). (D) 
Immunohistochemical staining with anti-MLH1 and anti-MSH2 antibodies of 
tumor sections derived from two CRC patients treated with FOLFOX+anti-EGFR 
monoclonal antibody panitumumab. Tumor sections were derived from the 
primary lesion at diagnosis (pre-treatment), and  at the time of partial response 
(PR) when the lesions shrank. Scale bar 0.1mm. Magnifications ×40 (scale bar 
0.05mm). 
 
 
 
Fig. 3. Targeted therapies trigger stress response, increase ROS levels and 
induce DNA damage in CRC cells. (A) CRC cells were treated as reported and 
fixed and stained with anti-γH2AX antibody at indicated time points. Vehicle 
treated cells (NT) were used as control. Nuclei are stained with DAPI (blue) and 
anti-γH2AX antibody (red). Scale bar: 50µm. Representative images for each 
condition are shown. (B) Quantification of nuclear γH2AX foci in DiFi (left panel) 
and WiDr (right panel) cells. Results represent means ± SD (n=3 for 48 and 72H; 
n=2 for 96H ). *p< 0.05; **p< 0.01; ***p< 0.001 (Two Way ANOVA). (C) CRC cells 
were treated as indicated and ROS levels were measured. NAC was used as a 
control to rescue ROS production. Results represent means of two independent 
experiments. *p< 0.05; **p< 0.01; ***p< 0.001 (Student’s t test). (D) CRC cells 
were treated with targeted therapies and analyzed by Western blot at indicated 
time points. (E) WT DiFi (left panel) and BRAF-mutated WiDr (right panel) cells 
were transfected with indicated siRNA or combinations of them for 72 hours and 
analyzed by Western blot. All star, non-targeting siRNA. 
 
 
 
 
 
 
Fig. 4. Treatment with targeted therapies promotes mutagenesis in CRC 
cells. (A) Schematic representation of the CA-NanoLuc reporter assay. MMRp, 
mismatch repair proficient; MMRd, mismatch repair deficient. (B) MMRd 
HCT116 and MMRp DiFi, WiDr and NCIH508 CRC cells were transduced with the 
NanoLuc lentivirus. At indicated time points NanoLuc signal was evaluated and 
normalized to cell viability. Results represent means ± SD (n=3). **p< 0.01; ***p 
< 0.001 (Student’s t test). Ns, not statistically significant differences. (C) NanoLuc 
signal in HT29 MLH1 knock-out (KO) clones (cl. 1 and cl. 2).  NanoLuc signal was 
evaluated after 72 and 96 hours of growth in standard conditions and 
normalized to cell viability. NanoLuc signal from MLH1 KO clones was then 
compared to signal detected in MLH1 WT cells (CTR). Results represent means ± 
SD (n=4). *p < 0.05; **p < 0.01; ***p < 0.001 (Student’s t test). (D) DiFi, WiDr, and 
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NCIH508 CRC cells were treated as indicated. NanoLuc signal was normalized to 
cell viability. NanoLuc signal from treated cells was then compared to signal 
detected in untreated (NT) cells. Results represent means ± SD (n=3). *p < 0.05; 
**p < 0.01; ***p < 0.001 (Student’s t test). 
 
Fig. 5. Adaptive mutability leads to genetic instability in CRC cells in 
response to therapy-induced stress. (A) Percentage of unstable microsatellite 
C
TR
L
0.0
0.1
0.2
0.3
0.4
0.5
A
lt
e
ra
ti
o
n
s
in
m
ic
ro
s
a
te
lli
te
re
g
io
n
s
(%
) DiFi
0.0
0.1
0.2
0.3
0.4
0.5
WiDr
A
0
1
2
3
4
5
WiDrC
D
P
D
X
V
eh
ic
le
C
TR
L
0.0
0.5
1.0
1.5
2.0
2.5
CRC0078
E
8
9
10
PDX Vehicle CTRL PDX CTX-R
***
L
e
n
g
th
o
f
M
ic
ro
s
a
te
lli
te
R
e
g
io
n
11
10
9
12
13
DiFi
***
DiFi
Resistant
L
e
n
g
th
o
f
M
ic
ro
s
a
te
lli
te
R
e
g
io
n
10
9
11
12
13
14
15
8
WiDr
L
e
n
g
th
o
f
M
ic
ro
s
a
te
lli
te
R
e
g
io
n
WiDr
Resistant
***
B
P
D
X
C
TX
-R
A
lt
e
ra
ti
o
n
s
in
m
ic
ro
s
a
te
lli
te
re
g
io
n
s
(%
)
P
er
si
st
er
s
R
es
is
ta
nt
C
TR
L
P
er
si
st
er
s
R
es
is
ta
nt
N
u
m
b
e
r
o
f
U
N
S
T
A
B
L
E
m
ic
ro
s
a
te
lli
te
lo
c
i
R
es
is
ta
nt
P
er
si
st
er
s
P
ar
en
ta
l T
0
A
lt
e
ra
ti
o
n
s
in
m
ic
ro
s
a
te
lli
te
re
g
io
n
s
(%
)
regions in DiFi and WiDr persister and resistant cells compared to their parental 
counterpart (CTRL). (B) Length distribution of one representative microsatellite 
region for drug-resistant DiFi and WiDr cell lines. ***p< 0.001 (χ2 test). (C) 
Number of unstable microsatellite sites detected by NGS-based high depth 
capture panel in WiDr cells (parental); treated with cetuximab + dabrafenib for 
14 days (persisters) and at resistance. (D) DNA was collected from one vehicle-
treated and from one cetuximab-resistant PDX. Percentage of unstable 
microsatellite regions of the tumor collected from the cetuximab-resistant 
mouse (PDX CTX-R) as compared to the vehicle-treated (CTRL) mouse is 
reported. (E) Length distribution of one representative microsatellite region. 
***p < 0.001 (χ2 test).  
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Materials and Methods 
Cell culture and generation of resistant CRC cells  
Cells were routinely supplemented with FBS 10%, 2mM L-glutamine, antibiotics 
(100U/mL penicillin and 100 mg/mL streptomycin) and grown in a 37°C and 5% 
CO2 air incubator. Cells were routinely screened for absence of Mycoplasma 
contamination using the Venor® GeM Classic kit (Minerva biolabs). The identity 
of each cell line was checked no more than three months before performing 
experiments by PowerPlex® 16 HS System (Promega), through Short Tandem 
Repeats (STR) tests at 16 different loci (D5S818, D13S317, D7S820, D16S539, 
D21S11, vWA, TH01, TPOX, CSF1PO, D18S51, D3S1358, D8S1179, FGA, Penta D, 
Penta E, and amelogenin). Amplicons from multiplex PCRs were separated by 
capillary electrophoresis (3730 DNA Analyzer, Applied Biosystems) and 
analyzed using GeneMapper v.3.7 software (Life Technologies). Persister cells 
were generated through continuous treatment for 2 weeks with 100µg/ml of 
anti-EGFR monoclonal antibody cetuximab (DiFi) or with 50µg/ml of cetuximab 
in combination with 1µM BRAF inhibitor dabrafenib (WiDr). Resistant cell lines 
employed in this study have been previously described (2, 51). 
Cetuximab was kindly provided by MERCK Group. 
 
Drug proliferation assays 
CRC cells were seeded at different densities (2-5x103 cells/well) in medium 
containing 10% FBS in 96-well plastic culture plates at day 0. The following day, 
serial dilutions of the indicated drugs were added to the cells in serum-free 
medium (ratio 1:1), while DMSO-only treated cells were included as controls. 
Plates were incubated at 37°C in 5% CO2 for the indicated time. Cell viability was 
assessed by measuring ATP content through Cell Titer-Glo® Luminescent Cell 
Viability assay (Promega).  
 
Time-To-Progression (TTP) assay   
For the TTP long-term assay, 5 million cells were plated in their respective 
growth media, as previously described (51), and treated from the following day 
with 100µg/ml cetuximab alone (DiFi), 50µg/ml cetuximab + 1µM dabrafenib 
(WiDr), 10mM NAC or a combination of the drugs as indicated. Cells were 
counted once a week. Counts reported as “0” represent time points in which cells 
were too few to be counted and only medium and drug refreshments were done. 
 
Q-RT-PCR  
Prior to analysis, cells were grown in their specific media supplemented with 
10% FBS and treated as follow: 100µg/ml of cetuximab (CTX) for DiFi and 
NCIH508; 50µg/ml cetuximab (CTX) + 1µM dabrafenib (DAB) for WiDr and 
HT29. Total RNA was extracted from CRC cells using Maxwell® RSC miRNA 
Tissue Kit (Promega), according to the manufacturer’s protocol. The 
quantification and quality analysis of RNA was performed by Thermo Scientific 
Nanodrop 1000 and Bioanalyzer 2100 (Agilent Technologies). DNA was 
transcribed using iScript RT Super Mix (BioRad) following the manufacturer's 
instructions. Q-RT-PCR was performed in triplicate on an ABI PRISM 7900HT 
thermal cycler (Life Technologies) with SYBR green (Promega) dye (MLH1, 
MSH2, MSH6, Polι) or TaqMan (Thermofisher) probes (BRCA1, BRCA2, EXO1, 
and Polκ). SDHA and GAPDH expression levels were used for normalization. The 
sequences of the primers (IDT) used for gene expression analyses were: MLH1 
FW 5’-CAGAGCTTGGAGGGGGATA-3’; MLH1 REV 5’- TTTCGGGAATCATCTTCCAC -
3’; MSH2 FW 5’- AACCCAAATCCATCGTAGGT -3’; MSH2 REV 5’- 
AACCCAAATCCATCGTAGGT -3’; MSH6 FW 5’- GGGGCAAGTCTACGCTTATG -3’; 
MSH6 REV 5’- CACACTTCAGCAGGGACGTA -3’; POLι FW 5’-
ACAAACCGGGATTTCCTACC-3’; POLι REV 5’-TCACACTTCCTTTCCCTTGAA-3’; 
SDHA FW 5’- TGGGAACAAGAGGGCATCTG-3’;SDHA REV 5’- 
CCACCACTGCATCAAATTCATG-3’. Taqman probe (ThermoFisher scientific) used 
are as follows: BRCA1 (Hs01556190_m1); BRCA2(Hs00609073_m1); EXO1 
(Hs00243513_m1); Pol κ (Hs00211965_m1), and GAPDH (Hs99999905_m1). 
 
Western blotting analysis 
Prior to biochemical analysis, cells were grown in their specific media 
supplemented with 10% FBS and treated as follow: 100µg/ml of cetuximab 
(CTX) for DiFi and NCIH508; 50µg/ml cetuximab (CTX) + 1µM dabrafenib (DAB) 
for WiDr and HT29. Following treatment, total cellular proteins were extracted 
by solubilizing the cells in boiling SDS buffer (50 mM Tris-HCl [pH 7.5], 150 mM 
NaCl, and 1% SDS). Samples were boiled for 5 minutes at 95°C and sonicated for 
10 seconds. Extracts were clarified by centrifugation and normalized with the 
BCA Protein Assay Reagent kit (Thermo). Western blot detection was performed 
with enhanced chemiluminescence system (GE Healthcare) and peroxidase 
conjugated secondary antibodies (Amersham). The following primary antibodies 
were used for western blotting: anti-MLH1 (abcam; 1:5000); anti-MSH2 (abcam; 
1:5000); anti-MSH6 (abcam; 1:5000); anti-PMS2 (Cell Marque Corporation, USA; 
1:10); anti EXO1 (abcam; 1:1000); anti-RAD51 (GeneTex; 1:500); anti BRCA2 
(Cell Signaling; 1:1000); anti-Polι (abcam; 1:1000); anti–phospho-p44/42 ERK 
(Thr202/Tyr204) (Cell Signaling; 1:1000); anti-ERK (Cell Signaling; 1:1000); 
anti-p-EGFR (Tyr1068) (Cell Signalling; 1:1000); anti-EGFR (EnzoLifeSciences; 
1:1,00); anti-BRAF (Santa Cruz; 1:500); anti-KRAS (Sigma Aldrich; 1:1000); anti-
actin (Santa Cruz; 1:3000); anti-Vinculin (Millipore; 1:3000); anti-p-mTOR 
(Ser2448) (Cell Signaling; 1:1000); anti-mTOR (Cell Signaling; 1:1000); anti-p-
p70S6K (Thr389) (Cell Signaling; 1:1000); anti-p70S6K Cell Signaling; 1:1000); 
anti-p-S6 (Ser235/236) (Cell Signaling; 1:1000); anti-p-AMPK (Thr172) (Cell 
Signaling; 1:1000); anti-AMPK (Cell Signaling; 1:1000); anti-pH2AX (Ser139) 
(Cell Signaling; 1:1000); anti-H2AX (Cell Signaling; 1:1000).  
 
Cell cycle analysis 
CRC cells were seeded at different densities (2-3x105 cells/well) in complete 
medium in 6-well plastic culture plates at day 0. The following day, the indicated 
treatments were added. Plates were incubated at 37°C in 5% CO2 for the 
indicated time. Following treatment, cells were stained with Propidium Iodide 
(Sigma Aldrich) following manufacturer’s instructions and analyzed by flow 
cytometry. 
 
Immunohistochemistry 
Patient tumor samples were obtained under the approval of the local Ethical 
committee of the Niguarda Cancer Center (MI) and of the Italian Ministry of 
Health. Tumor sections were formalin-fixed, paraffin-embedded, and processed 
according to standard procedures using Envision Flex+, Mouse, High pH (DAKO) 
and PT link (DAKO). Sections were analyzed with the following antibodies: anti-
MLH1 (BD transduction Laboratories; 1:40); anti-MSH2 (Calbiochem; 1:50). 
 
Immunofluorescence 
CRC cells, grown on glass coverslip, were fixed in 4% paraformaldehyde for 20 
min at RT and permeabilized with 0.1% Triton-X100 in PBS for 2 min on ice. 
Then, cells were treated at RT with 1% BSA in PBS for 30 min and incubated for 
2h at room temperature (RT) with the following primary antibodies diluted in 
PBS containing 1% of BSA and 1% of donkey serum: anti-MLH1 (BD Pharmigen) 
(1:200); anti-Polι (1:200) (GeneTex). After washing, cells were fluorescently 
labeled, according to the primary antibody used, with an Alexa Fluor® 555 
donkey anti-mouse antibody or Alexa Fluor® 488 donkey anti-rabbit antibody 
(Molecular Probes, Eugene, USA) diluted 1:400 in PBS containing 1% BSA and 
donkey serum for 1h. Nuclei were stained with DAPI. F-actin was stained with 
Alexa Fluor® 647 Phalloidin (50 μg/ml). Slides were then mounted using the 
fluorescence mounting medium (Dako, Glostrup, DK) and analyzed using a 
confocal laser scanning microscope (TCS SPE II; Leica, Wetzlar, D). For 
immunofluorescence detection of γ-H2AX and 53BP1 foci, cells were stained 
with the anti-phospho-Histone H2AX (Ser139) rabbit monoclonal antibody 
(Bethyl Laboratories) (1:600), anti-53BP1 rabbit polyclonal antibody (Cell 
Signaling) (1:100) and Alexa555 goat anti-rabbit IgG secondary (Thermo Fisher) 
(1:400). A Leica DMI6000B fluorescence microscope (Leica Microsystems, 
Wetzlar, Germany) under a 40X dry objective was used to detect γ-H2AX and 
53BP1 foci. Images were captured at 10 individual z-planes and were merged 
using the “Z Project” function in ImageJ. Individual nuclei were scored for foci 
positivity as identified based upon signal intensity above general background 
staining levels and presence within the nucleus as assessed by DAPI staining. 
Cells containing ≥ 5 distinct foci were defined as foci-positive, and the 
percentage of positive nuclei was calculated as [(number of γ-H2AX foci positive 
nuclei) / (number of nuclei scored)]* 100. A minimum of 500 nuclei per sample 
were scored and the data shown were collected from two biological replicates. 
Statistical significance of the experimental data was determined using Two-Way 
ANOVA as indicated in the figure legend in GraphPad (Prism7). Where indicated, 
CRC cells were treated as follow: 10 or 100µg/ml of cetuximab (CTX) for DiFi; 
50µg/ml cetuximab (CTX) + 250nM or 1µM dabrafenib (DAB) for WiDr at 
indicated time points. 
 
CRC cell transduction 
The NanoLuc expressing plasmid was provided by PhoreMost Ltd (Cambridge, 
UK). The sequence of the NanoLuc enzyme (NanoLuc® Promega) is cloned 
downstream of a stretch of 18 CA-dinucleotide repeats (microsatellite region). In 
this condition, the luciferase cDNA is out-of-frame and does not encode a 
functional enzyme. The random introduction of indels in the CA18 sequence 
restores the NanoLuc open reading frame and leads to the expression of the 
NanoLuc measurable by luminescence. Lentiviral particles were generated by co-
transfection of HEK293T cells with the viral vector and packaging plasmids 
pVSVg (AddGene #8454) and psPAX2 (AddGene #12260). CRC cell lines were 
seeded at 25 × 104 cells/well in 6-well plastic culture plates. The following day, 
cells were infected with lentivirus at approximately 80% confluence in the 
presence of 8μg/mL polybrene (Millipore). Seventy-two hours after infection, 
puromycin (Sigma Aldrich) or blasticidin (Gibco) were used to select stably 
infected cells.  
 
NanoLuc assay 
CRC cells were seeded at 2-3x103 cells/well in 96-well plastic cell culture plates 
at day 0. The following day, cells were treated with targeted therapies as follow: 
10 or 100µg/ml of cetuximab (CTX) for DiFi and NCIH508; 50µg/ml cetuximab 
(CTX) + 250nM or 1µM dabrafenib (DAB) for WiDr at indicated time points. At 
the end of treatment, NanoLuc expression was measured using NanoGlo® 
Luciferase Assay System (Promega) according to manufacturer’s instruction. 
Luminescence was measured by TECAN Spark® Plate reader. The NanoLuc 
signal was normalized to the viability measured through Cell Titer-
Glo®Luminescent Cell Viability assay (Promega). 
 
MMR assay 
The MMR assay was performed as previously described (27). Cells were seeded 
at 25 × 104 cells/well in 6-well plastic culture plates. The following day, cells 
were transfected with a mixture containing 700ng of pmax-vector; 150ng of 
pmax-BFP and 150ng pmax-mOrange (G:C undamaged control) or with pmax-
G:G-mismatch containing-mOrange (damaged MMR) using Lipofectamine 3000 
following manufacturer’s instruction. The MMR reporter is designed to express a 
non-fluorescent orange protein unless the site-specific G:G mismatch is repaired 
in a manner that restores the wild-type sequence in the transcribed strand (27). 
Immediately after transfection, cells were treated as follow: 100µg/ml cetuximab 
(CTX) for DiFi or 50µg/ml cetuximab (CTX) + 1µM dabrafenib (DAB) for WiDr. 
Fifty to sixty hours after transfection cells were harvested and analyzed by flow 
cytometry. The pmax-BFP was used as internal control for transfection efficiency 
to normalize the mOrange signal. The relative MMR capacity was determined by 
dividing the percentage of mOrange positive cells in damaged MMR by the 
percentage of mOrange positive cells in undamaged control.  
 
Generation of pDRGFP expressing cells 
The CRC cells WiDr and DiFi were seeded at 25 × 104 cells/well in 6-well plastic 
culture plates. The following day, cells were transfected with pDRGFP plasmid 
(AddGene) using Lipofectamine 3000 following manufacturer’s instruction. 
pDRGFP plasmid is composed of two differentially mutated GFP 
(green  fluorescent protein) genes oriented as direct repeats and separated by a 
drug selection marker (28). One of the GFP genes is mutated to contain the 
recognition site for the Sce-I endonuclease and, as a result, will undergo a DSB 
when Sce-I is ectopically expressed (28). A homologous recombination event 
between the two GFP genes results in the expression of intact GFP protein. 
Seventy-two hours after infection, puromycin (Sigma Aldrich) was used to select 
stably infected cells. 
 
HR assay 
The pDRGFP-expressing cells were seeded at 25 × 104 cells/well in 6-well plastic 
culture plates. The following day, cells were transfected with the Sce-I -
expressing plasmid (pCBASce-I; AddGene) (28) using Lipofectamine 3000 
following manufacturer’s instruction. Immediately after transfection, cells were 
treated with 100µg/ml cetuximab (DiFi) or with 50µg/ml cetuximab + 1µM 
dabrafenib (WiDr). Fifty to sixty hours after transfection, cells were harvested 
and analyzed by flow cytometry. The relative HR capacity was determined by 
dividing the percentage of GFP-positive cells in Sce-I transfected cells by the 
basal percentage of GFP signal in mock control.  
 
siRNA screening 
The siRNA targeting reagents were purchased from Dharmacon, as a SMARTpool 
of four distinct siRNA species targeting different sequences of the target 
transcript. Cell lines were grown and transfected with SMARTpool siRNAs using 
RNAiMAX (Invitrogen) transfection reagents following manufacturer’s 
instructions. Briefly, RNAi screening conditions were as follows: on day one, 
siRNA were distributed in each well of a 6-well plate at the final concentration of 
20 nmol/L. Transfection reagents were diluted in OptiMEM and aliquoted at 
250µl/well. After 20 minutes of incubation, 2ml of cells in media without 
antibiotics were added to each well. After 72 hours, cells were analyzed by 
Western blot. AllStars (Qiagen) non-targeting siRNA was used as negative 
control. 
 
Generation of patient derived xenografts 
Patient tumor sample was obtained under the approval of the local Ethical 
committee of the institution and of the Italian Ministry of Health. To perform 
animal experiments on PDXs (patient-derived xenografts), tumor specimens 
were subcutaneously propagated in NOD-SCID mice (Charles River Laboratory). 
When tumors reached nearly 300 mm3 in volume, cetuximab (Merck, 10 mg/kg) 
was administered twice/week by intraperitoneal injection. Tumor size was 
evaluated weekly by caliper measurements, and the volume of the mass was 
calculated using the formula V = (d2×D)/2 (d = minor tumor axis; D = major 
tumor axis) and reported as tumor mass volume (mm3). Animal procedures were 
approved by the Ethical Commission of the Candiolo Cancer Institute and by the 
Italian Ministry of Health. 
 
CRISPR/Cas9 MLH1 knock-out 
To generate the MLH1 knock-out, we used the genome editing one vector system 
(lentiCRISPR-v2) (Addgene plasmid: 52961). Small guide RNAs (sgRNAs) were 
designed using the CRISPR tool (http://crispr.mit.edu). Annealed sgRNA 
oligonucleotides targeting the human MLH1 gene were cloned into Bsmbl 
lentiCRISPR-v2 plasmid as previously described(52). For transient expression of 
CRISPR-Cas9 system, cells were transfected with lentiCRISPR-v2 vector plasmid. 
Transfection was carried out using Lipofectamine 3000 (Life technologies) and 
OptiMEM (Invitrogen), according to the manufacturer’s instructions. After 48 
hours, cells were incubated with puromycin (Sigma Aldrich) for 4 days and 
subsequently single cell diluted in 96-well plates. Two independent clones (cl.1 
and cl.2) were selected and loss of MLH1 protein expression and absence of Cas9 
were confirmed by Western blot. HT29 cells transfected with non-targeting 
(empty) sgRNA were used as control. 
 
ROS production assay 
DiFi and WiDr parental and derivative resistant cells were seeded in 96-well 
white-walled plates (12 × 103 cells/well for DiFi and 6 × 103 cells/well for WiDr) 
and incubated overnight for attachment. The following day, cells were treated as 
follow: 50 µg/ml cetuximab for DiFi; 1 µM dabrafenib + 20 µg/ml cetuximab for 
WiDr. After 48, 72, and 96 hours ROS were measured by ROS-Glo™ H2O2 Assay 
(Promega) according to the manufacturer's protocol. Luminescence was 
measured using a plate-reading luminometer (TECAN Spark 10M) and the 
resulting data were normalized to untreated cells at each time point. The 
antioxidant N-acetyl-cysteine (NAC, Sigma) was used at the final concentration of 
10 mM as a control for the rescue experiment.  
 
RNAseq data analysis 
Prior to analysis, cells were grown in their specific media supplemented with 
10% FBS and treated as follow: 100µg/ml of cetuximab (CTX) for DiFi; 50µg/ml 
cetuximab (CTX) +1µM dabrafenib (DAB) for WiDr. 
Total RNA was extracted using Maxwell® RSC miRNA Tissue Kit (AS1460, 
Promega), according to the manufacturer’s protocol. The quantification of RNA 
was performed by DS-11 Spectrophotometer (DeNovix) and Qubit 3.0 
Fluorometer (Life Technologies).  
RNA integrity was evaluated with the Agilent 2100 Bioanalyzer using the Agilent 
RNA 6000 Nano Kit. Total RNA (500 ng) with RNA integrity number (RIN) score 
between 9 and 10 was used as input to the Illumina TruSeq RNA Sample Prep Kit 
v2-Set A and B (48Rxn), according to the manufacturer’s protocol. 
The standard RNA fragmentation profile was used (94 °C for 8 min for the 
TruSeq RNA Sample Prep Kit). RNA-seq library quality was assessed using the 
Agilent DNA 1000 kit on the Agilent 2100 BioAnalyzer and quantified using 
Qubit 3.0 Fluorometer (Life Technologies). Libraries were diluted to 10 nM using 
Tris-HCl (10 mM pH 8.5) and then pooled together. Diluted pools were denatured 
according to the standard Illumina protocol. 
FastQ files produced by Illumina NextSeq500 were aligned using MapSplice2 
(53) transcriptome-aware aligner using hg38 assembly as reference genome. The 
resulting BAM files were post-processed to translate genomic coordinates to 
transcriptomic ones and to filter out alignments carrying insertion or deletions 
or falling outside the transcriptome regions. The post-processed BAM alignment 
was given as input to RSEM (54) for gene expression quantification using 
GENCODE (55) v22 as gene annotation. 
 
Whole exome sequencing and mutational burden calculation 
Library preparation, enrichment of whole exome regions, and sequencing were 
performed by Integragen SA (Evry, France) according to standard protocols (56). 
Bioinformatic analysis was performed as previously reported (57). The FASTQ 
sequence files were pre-processed to remove adapter sequences using 
“agilentreadtrimmer” and were then mapped to the human genome version 19 
(hg19) using BWA-mem algorithm. For PDX samples, mouse-derived reads were 
distinguished by human reads and removed using XENOME (58). PCR duplicates 
were removed using the RMDUP command of SAMtools package. The median 
depth for each sample is reported in Table S1. Targeted regions covered by at 
least 40 reads were between 87.6% and 95.1%. The mutational burden (MB) 
was calculated from WES data taking into consideration nucleotide variants 
supported by a minimum of 4 mutated reads in regions with a minimum depth of 
5X. We considered only mutations with allele frequency higher than 10%, 
excluding mutations annotated in dbSNP (v147) and somatic mutations relevant 
in cancer annotated in COSMICdb (v75). All data were also normalized on 
specific covered target regions. 
 
Analysis of homopolimer and microsatellite genomic regions 
The overall bioinformatic approach is based on previously published literature 
(59). Specifically, the reference genome (human genome version 19) was 
analyzed to identify homopolimer and microsatellite genomic regions up to five 
nucleotides in length and with at least five consecutive repeats. A total of 
33,386,402 regions were identified. Using WES data, reads located in one of the 
identified regions were extracted. Regions with less than 20 encompassing reads 
in one of two paired samples were discarded. At least 11,000 regions for each 
pair were included in the analysis. Read lengths of pre- and post-therapy 
samples were measured, and the distribution for each sample pair was 
calculated. Next, a standard χ2 test was performed for each region (pre- and 
post-therapy). A region was considered unstable when the χ2 p-value was less 
than 0.05. The percentage of unstable regions is defined as the ratio between the 
number of unstable regions and the total number of regions included in the 
analysis for each pair. 
 
NGS high depth capture panel 
The NGS high depth capture panel is designed on hotspots of 42 target genes 
relevant for colorectal cancer. The genomic size is 55 kilobases for a total of 300 
captured regions. All coding sequences of all isoforms of 8 clinical relevant genes 
are included: APC, BRAF, ERBB2, MET, TP53 and MMR pathway genes (MLH1, 
MSH2 and MSH6). The target panel is characterized by the presence of tandem 
repeats sequences (5 loci) useful to determine the stability of microsatellite 
regions (MSI status). A list of 54 single-nucleotide polymorphisms (SNPs) was 
used to identify the allelic profile and to build the single-nucleotide 
polymorphism identifier (SNP_ID) of each sample. The regions captured are 
reported in Table S2. Libraries preparation methods optimized for analysis of 
small targets were applied (60, 61). 
 
Statistical Analyses 
Statistical significance was determined by two-tailed Student’s t-test or TwoWay 
ANOVA (GraphPad Prism) as specified for each experiment and p <0.05 was 
considered statistically significant. 
 
  
Fig. S1.  Cell cycle arrest, generation of persister cells and alteration of DNA repair 
genes in CRC cells treated with targeted agents. (A) DiFi and WiDr cells were treated 
as indicated for 96 hours. Cell viability was assayed by the ATP assay. Bars represent 
means ± SD of three technical replicates. (B) DiFi and WiDr cell lines were treated with 
50µg/ml cetuximab alone (DiFi) or in combination with 1µM dabrafenib (DAB) (WiDr). 
Untreated cells (NT) were used as control. Ninety-six hours later, cells were analyzed by 
flow cytometry. Distribution of cells in G1, S and G2 phases is reported in the bar graph. 
(C-D) DiFi cells were treated with 100µg/ml of cetuximab (CTX), and WiDr were treated 
with 50µg/ml cetuximab + 1µM dabrafenib (DAB) for 96h or for 2 weeks (PERSISTERS). 
Representative cells images are shown. NT, untreated control cells. (E-F) DiFi and WiDr 
cells were treated for 2 weeks with cetuximab (CTX) alone or in combination with 
dabrafenib, respectively, till drug-tolerant cells survived (PERSISTERS). Cells were then 
either released from drug pressure (RELEASE) or continuously treated until resistance 
arose (RESISTANT). After that, viability of resistant cells upon drug withdrawal (RES-
REL) was further measured. NT, untreated control parental cells. (G-H) Ninety-six hours 
after administration of cetuximab (DiFi) or cetuximab + dabrafenib (WiDr) the 
expression of the indicated genes was evaluated by RT-PCR. Results represent means ± 
SD of at least 3 independent experiments. **p< 0.01; ***p< 0.001 (Student’s t test). NS, 
not statistically significant differences. 
 
 
 
 
 
Fig. S2. Alteration of DNA repair in CRC cells. (A) CRC cells were treated for 72 hours 
as indicated. After that cells were fixed and stained. Vehicle-treated cells (NT) were used 
as control. Nuclei were stained with DAPI (blue) and anti-MLH1 antibody (green). Actin 
was stained with Phalloidin (red). Scale bar: 25µm. Representative images of each 
condition are shown. (B) CRC cells were treated for 72 hours as reported. After that cells 
were fixed and stained. Vehicle-treated cells (NT) were used as control. Nuclei were 
stained with DAPI (blue) and anti-Polι antibody (green). Actin was stained with 
Phalloidin (red). Scale bar: 50µm. Representative images of each condition are reported. 
DAB, dabrafenib; CTX, cetuximab. 
 
 
 
 
 
 
 
 
 
Fig. S3. Down-modulation of MMR and HR genes in CRC cells sensitive to targeted 
therapies. (A) NCIH508 cells were treated with the indicated concentration of 
cetuximab for 96h. Cell viability was assayed by ATP assay. Bars represent means ± SD 
of three technical replicates. (B) NCIH508 cells were treated and analyzed at indicated 
time points by Western blot.  (C) Ninety-six hours after cetuximab administration, the 
expression of the indicated genes was evaluated by RT-PCR. Bars represent means of 
two independent experiments. *p < 0.05; **p< 0.01; ***p< 0.001  (Student’s t test). NS, 
not statistically significant differences. (D) HT29 cells were treated with indicated 
therapeutic regimens for 96h. Cell viability was measured by ATP assay. Bars represent 
means ± SD of three technical replicates. (E) HT29 cells were treated and analyzed at 
indicated time points by Western blot. DAB, dabrafenib; CTX, cetuximab. NT, untreated 
cells. 
 
 
  
 
 
 
 
Fig. S4. Analysis of DNA repair effectors in persisters cells. (A) DiFi and WiDr cells 
were treated for 2 weeks until the persister state was reached and RNAseq analysis was 
then performed. Mismatch repair (MMR) (yellow), homologous recombination (HR) 
(green), and DNA polymerases (blue) genes are reported. Results represent means of 
two independent experiments. (B) Expression levels of MMR and HR DNA repair 
proteins were evaluated in 2 independent persister populations (P1 and P2) for each 
cell line model. NT stands for untreated cells. (C) Persisters cells and vehicle-treated 
cells (NT) were fixed and stained. Nuclei were stained with DAPI (blue) and anti-MLH1 
antibody (green). Actin was stained with Phalloidin (red). Scale bar: 25µm. 
Representative images of each condition are reported. (D) Persisters cells and vehicle-
treated cells (NT) were fixed and stained. Nuclei were stained with DAPI (blue) and anti-
Polι antibody (green). Actin was stained with Phalloidin (red). Scale bar: 50µm. 
Representative images of each condition are reported. 
  
 
 
Fig. S5. Transient modulation of DNA repair proteins by drug treatment. (A) 
Modulation of DNA repair proteins was measured upon withdrawal of targeted 
therapies. The indicated parental cells were treated with either cetuximab (CTX) alone 
(DiFi and NCIH508) or in combination with dabrafenib (DAB) (WiDr) for 72, 96, and 120 
hours. Treatment was then removed for additional 72 (72W) or 96 (96W) hours and 
protein expression was analyzed by Western blot. (B) DiFi and WiDr parental and 
permanently resistant (-R) derivatives were treated with 50µg/ml of cetuximab (CTX) 
alone or in combination with 1µM dabrafenib (DAB) and protein expression was 
analyzed by Western blot. (C) Ninety-six hours after indicated drugs treatment, resistant 
cells were fixed. Cells were stained with DAPI (blue-nuclei) and anti-MLH1 antibody 
(green). Actin was stained with Phalloidin (red). Scale bar: 25µm. Representative images 
of each condition are reported. NT, untreated cells. 
 
 
 
 
Fig. S6. Drugs targeting EGFR and BRAF influence MMR and HR capabilities of CRC 
cells. (A) The indicated CRC cells were transfected with G:C undamaged plasmid or with 
G:G mismatch-damaged (MMR) plasmid. Where indicated (DRUG), cells were treated 
with targeted therapies for fifty-sixty hours and analyzed by flow cytometry. A mock 
transfection was used as control. The pmax-BFP (VIOLET channel) was used as internal 
control for transfection efficiency to normalize the mOrange (PE channel) signal. MMR 
deficient CRC cells LIM1215 were used as a positive control for MMR loss. Results of one 
representative experiment are reported. (B) pDRGFP-stably expressing CRC cells were 
transfected with the pCBASce-I plasmid and then either left in the absence of drug or 
treated with targeted therapies (DRUG) for fifty-sixty hours and analyzed by flow 
cytometry. A mock transfection was used as control. Results of one representative 
experiment are reported. 
 
 
  
 
 
 
Fig. S7. Altered expression of MMR proteins in PDXs treated with cetuximab. (A-D) 
Tumor regression in the indicated PDX models after treatment with cetuximab (CTX) 
(20 mg/kg twice weekly) for 6 weeks. Growth curve kinetics are shown in the upper 
panels. Mean tumor volumes ± SEM are shown (n = 6 mice per treatment arm). 
Immunohistochemical analysis with anti-MLH1 and anti-MSH2 antibodies of histologic 
tumor sections derived after 6 weeks of cetuximab administration are shown in the 
lower panels. Tumor sections derived from placebo arm were used as control. Scale bar 
0.1mm. Magnifications ×40 (scale bar 0.05mm).  
 
 
 
 
Fig. S8. Monitoring DNA damage in persisters and resistant CRC cells. (A) DiFi (left) 
and WiDr (right) persisters cells and vehicle-treated control (NT) were fixed and 
stained. Nuclei were stained with DAPI (blue) and anti-γH2AX antibody (red). Scale bar: 
50µm. Representative images of each condition are shown. (B) Quantitation of nuclear 
γH2AX foci in DiFi and WiDr untreated (NT) and persisters cells. Nuclei with five or 
more γH2AX foci were scored as positive, and at least 500 nuclei were counted for each 
sample. Results represent means ± SD (n=3). ***p <0.001 (Two Way Anova). NS, not 
statistically significant differences. (C) Resistant CRC cells (-R) were treated as 
indicated. After indicated time points, cells were fixed and stained. Vehicle-treated cells 
(NT) were used as control. Nuclei were stained with DAPI (blue) and anti-γH2AX 
antibody (red). Scale bar: 50µm. Representative images of each condition are shown. (D) 
Quantitation of nuclear γH2AX foci in DiFi resistant (upper panel) and WiDr resistant 
(lower panel) untreated or treated cells. Nuclei with five or more γH2AX foci were 
scored as positive, and at least 500 nuclei were counted for each sample. Results 
represent means of two independent experiments. NS, not statistically significant 
differences. DAB, dabrafenib; CTX, cetuximab. 
 
 
 
 
 
 
 
 
 
Fig. S9. Drug-induced switch from HR to NHEJ-mediated DSB repair. (A) Detection 
of 53BP1 foci in the indicated CRC cells. Vehicle-treated cells (NT) were used as control. 
Cells were fixed and stained after 72 hours of treatment. Nuclei were stained with DAPI 
(blue) and anti-53BP1 antibody (red). Scale bar: 50µm. Representative images for each 
condition are shown. (B) Quantification of nuclear 53BP1 foci in DiFi and WiDr cells 
after indicated treatment schedules. Nuclei with five or more 53BP1 foci were scored as 
positive and at least 500 nuclei were counted for each sample. Results represent means 
of two independent experiments. *p<0.05; **p< 0.01 (Two Way ANOVA). DAB, 
dabrafenib; CTX, cetuximab. (C) Resistant cells (-R) were treated with 50µg/ml of 
cetuximab (DiFi) or 20µg/ml cetuximab + 1µM dabrafenib (WiDr) and ROS levels were 
measured. Results represent means of two independent experiments. DAB, dabrafenib; 
CTX, cetuximab. 
 
 
 
 
 
Fig. S10. Effect of ROS modulation on CRC cells treated with targeted therapies. (A) 
Detection of γH2AX foci in the indicated CRC cells. Vehicle-treated cells (NT) were used 
as control. Cells were fixed and stained at indicated time points. Nuclei were stained 
with DAPI (blue) and anti-γH2AX antibody (red). Scale bar: 50µm. Representative 
images for each condition are shown. (B) Quantification of nuclear γH2AX foci in DiFi 
(left panel) and WiDr (right panel) cells after indicated treatment schedules. Nuclei with 
five or more γH2AX foci were scored as positive and at least 500 nuclei were counted for 
each sample. Results represent means of two independent experiments. **p< 0.01 (Two 
Way ANOVA). NS, not statistically significant differences. DAB, dabrafenib; CTX, 
cetuximab. (C) CRC cells were treated with 100µg/ml cetuximab (CTX) (DiFi), 50µg/ml 
cetuximab + 1µM dabrafenib (DCTX) (WiDr), 10mM NAC or their combinations (N+C; 
N+DC) for 72 hours. Cell protein lysates were analyzed by Western blot. NT, untreated 
control cells. (D) CRC cells were treated with cetuximab (CTX), dabrafenib + cetuximab 
(DAB + CTX), NAC their combinations for 5 days. Cell viability was assayed by the ATP 
assay. Bars represent means ± SD of three technical replicates. (E) BRAF-mutated WiDr 
cells and RAS/RAF WT DiFi were treated with 10mM NAC alone, MAPK pathway 
inhibitor(s) or combination of both until secondary resistance emerged. DAB, 
dabrafenib; CTX, cetuximab.  
 
 
 
 
 
 
 
 
Fig. S11. Impact of different types of stress on CRC cells. (A) DiFi and WiDr cell lines 
were treated with two cycles of thymidine (THY) administration and, after that, cells 
were analyzed by flow cytometry. (B) Distribution of cells in G1, S and G2 phases upon 
double-block with thymidine (THY). (C) Western blot analysis of MMR and HR proteins 
upon double-block with thymidine (THY). (D) DiFi and WiDr cell lines were treated with 
10µM oxaliplatin (OXAL) and, after that, cells were analyzed by flow cytometry. (E) 
Distribution of cells in G1, S and G2 phases upon oxaliplatin treatment at indicated time 
points. (F) CRC cells were treated with 10µM oxaliplatin (OXAL) for 72 and 96 hours, 
after that protein lysates were analyzed by Western blot. NT, untreated cells. (G) DiFi 
and WiDr cell lines were grown in medium without serum (0% FBS) for 24 hours; after 
that, cells were analyzed by flow cytometry. Cells grown in standard culturing 
conditions (10% FBS) were used as control. (H) Distribution of cells in G1, S and G2 
phases after 24 hours in standard culture conditions (10% FBS) or upon serum 
starvation (0% FBS). (I) CRC cells were cultured for 24 hours in 10% FBS or in 0% FBS 
media and analyzed by Western blot. 
 
 
 
 
 
 
 
 
Fig. S12. Silencing of driver oncogenes triggers ROS induction in CRC cells WT DiFi 
and BRAF p.V600E-mutated WiDr cells were transfected with the indicated siRNAs or 
combinations of them. Seventy-two hours after siRNA transfection ROS levels were 
measured. Results represent means ± SD (n=3).  All*, non-targeting siRNA. 
 
 
Fig. S13. Knock-out of the MLH1 gene in HT29 CRC cells. (A) CRISPR/CAS9-mediated 
knock-out (KO) of MLH1 gene in HT29 CRC cells was validated at the protein level. CTR 
stands for control cells (with intact MLH1 gene); cl.1 and cl.2 are two independent 
MLH1-KO clones. (B) Exome sequencing data were used to identify molecular 
alterations in the MLH1 gene in the genome-edited HT29 cells. Alignment of sequence 
reads harboring deletions of the MLH1 gene after gene editing is shown. The upper 
sequence corresponds to the human reference assembly hg19. CTR stands for control 
cells (with intact MLH1 gene); clone 1 carries heterozygous deletions (1 base pairs and 4 
base pairs) that induced frameshifts (100%); clone 2 carries a homozygous deletion that 
produced a frameshift (100%).  
 
 
Fig. S14. Mutagenic assays in drug-resistant CRC cells. CRC resistant (-R) cells were 
treated with the indicated therapeutic regimens. NanoLuc signal from treated and 
untreated (NT) resistant cells was normalized to cell viability. NanoLuc signal from 
treated cells was compared to untreated (NT) cells. Results represent means ± SD (n=4 
for DiFi; n=2 for WiDr).  
 
 
 
 
 
 
 
 
Fig. S15. Whole exome sequencing analysis of CRC cells upon drug-induced stress. 
Mutational burden (number of mutations/megabase) was measured using whole exome 
sequencing data in DiFi (A), and WiDr (B) cells. Only mutations with allele frequency 
above 10% were considered. Mutations annotated as SNP in dbSNP (v147) and somatic 
mutations relevant in cancer and annotated in COSMICdb (v75) were filtered out. 
Insertion/deletions (INDEL) and Single Nucleotide Variations (SNV) are reported. Data 
were normalized on the specific covered target region of each WES. 
 
 
 
 
 
 
 
 
Fig. S16. Molecular landscape of CRC cells upon genetic disruption of the MLH1 
gene. (A) Mutational burden (number of mutations/megabase) was measured using 
whole exome sequencing data. Only mutations with allele frequency above 10% were 
considered. Mutations annotated as SNP in dbSNP (v147) and somatic mutations 
relevant in cancer and annotated in COSMICdb (v75) were filtered out. 
Insertion/deletions (INDEL) and Single Nucleotide Variations (SNV) are reported. Data 
were normalized on the specific covered target region of each WES. (B) Percentage of 
unstable microsatellite regions in MLH1-KO cells clone 1 (cl.1) and clone 2 (cl.2) 
compared to their parental counterpart (EMPTY CTRL). (C) Lengths distribution of one 
representative microsatellite region for HT29 MLH1-KO clone 1 and clone 2 is reported. 
***p < 0.001 (χ2 test).  
 
 
 
 
 
 
 
Fig. S17. Alteration of microsatellite regions in WiDr cells. Lengths distribution of 
the 5 unstable sites included in the NGS high depth capture panel are reported. Chr, 
Chromosome. *** p<0.001 (χ2 test). 
 
 
 
 
 
 
Fig. S18. Emergence of secondary resistance to cetuximab in a patient-derived 
xenograft. Patient-derived mice models (PDX) were established from a tumor obtained 
from a metastatic colorectal cancer patient (CRC0078) with a RAS/RAF wild-type tumor. 
Upon successful engraftment, mice were randomized to vehicle (CTRL) or cetuximab-
treated arm as reported. Results represent tumor mass volume (mm3) of one PDX that 
developed cetuximab resistance and of the corresponding vehicle-treated control 
mouse. Blue arrow indicates treatment start. 
 
 
 Sample ID 
Coverage 
(depth > 40X) 
Coverage  
(depth > 1X) Median Depth 
 Whole Exome Sequencing 
DiFi_parental 92.6301 98.4883 111 
DiFi_Persisters 90.4104 98.5003 97 
DiFi_Resistant 91.8776 98.3399 113 
WiDr_parental 94.5697 98.5403 118 
WiDr_Persisters 93.0298 98.5398 104 
WiDr_Resistant 95.1203 98.5626 125 
PDX Vehicle CTRL 87.62 97.78 114 
PDX CTX-R 89.11 98.21 94 
 High depth capture panel 
WiDr_parental 99.5962 99.5223 8657 
WiDr_Persisters 99.5962 99.5259 11337 
WiDr_Resistant 99.5962 99.5259 11802 
 
Table S1. NGS sequencing depth. The table lists exome sequencing median depth for 
the indicated CRC models. Mouse-derived reads were filtered out in case of  patient-
derived xenograft (PDX Vehicle CTRL and PDX CTX-R) data.  
 
 
 
 
 
 
 
Chrom
. 
Start Stop Description Chrom
. 
Start Stop Descriptio
n 
chr14 10525893
4 
10525905
9 
AKT1-exon2 chr17 37872553 37872686 ERBB2 
chr14 10524642
5 
10524655
3 
AKT1-exon3 chr17 37872767 37872858 ERBB2 
chr14 10524299
5 
10524310
7 
AKT1-exon4 chr17 37873572 37873733 ERBB2 
chr3 41265559 41265573 CTNNB1-exon2 chr17 37876039 37876087 ERBB2 
chr3 41266016 41266244 CTNNB1-exon3 chr17 37879571 37879710 ERBB2 
chr7 55227831 55228031 EGFR-exon12 chr17 37879790 37879913 ERBB2 
chr7 55241613 55241736 EGFR-exon18 chr17 37880164 37880263 ERBB2 
chr7 55242414 55242513 EGFR-exon19 chr17 37880978 37881164 ERBB2 
chr7 55248985 55249171 EGFR-exon20 chr17 37881301 37881457 ERBB2 
chr7 55259411 55259567 EGFR-exon21 chr17 37881579 37881655 ERBB2 
chr16 30129669 30129859 MAPK3-exon3 chr17 37881959 37882106 ERBB2 
chr16 30129367 30129484 MAPK3-exon4 chr17 37882814 37882912 ERBB2 
chr16 30128214 30128324 MAPK3-exon7 chr17 37883067 37883256 ERBB2 
chr16 30127988 30128111 MAPK3-exon8 chr17 37883547 37883800 ERBB2 
chr22 22160139 22160329 MAPK1-exon3 chr17 37883941 37884297 ERBB2 
chr22 22127161 22127271 MAPK1-exon7 chr7 11633913
8 
11634033
8 
MET 
chr6 15226530
7 
15226564
3 
ESR1-exon6 chr7 11637172
1 
11637191
3 
MET 
chr6 15241986
6 
15242010
1 
ESR1-exon10 chr7 11638000
3 
11638013
8 
MET 
chr7 14850871 14850881 EZH2-exon16 chr7 11638090 11638107 MET 
6 2 5 9 
chr10 12327949
2 
12327968
3 
FGFR2-exon7 chr7 11639540
8 
11639556
9 
MET 
chr10 12327463
0 
12327483
3 
FGFR2-exon9 chr7 11639749
0 
11639759
3 
MET 
chr10 12325800
8 
12325811
9 
FGFR2-exon12 chr7 11639769
1 
11639782
8 
MET 
chr10 12324750
4 
12324762
7 
FGFR2-exon14 chr7 11639851
2 
11639867
4 
MET 
chr4 1803561 1803752 FGFR3-exon7 chr7 11639939
0 
11639954
4 
MET 
chr4 1806056 1806247 FGFR3-exon9 chr7 11640310
3 
11640332
2 
MET 
chr4 1807777 1807900 FGFR3-exon14 chr7 11640969
8 
11640984
5 
MET 
chr4 1808272 1808410 FGFR3-exon16 chr7 11641155
1 
11641170
8 
MET 
chr19 3114941 3115070 GNA11-exon4 chr7 11641190
2 
11641204
3 
MET 
chr19 3118921 3119051 GNA11-exon5 chr7 11641493
4 
11641516
5 
MET 
chr9 80409378 80409508 GNAQ-exon5 chr7 11641744
2 
11641752
3 
MET 
chr20 57484404 57484478 GNAS-exon8 chr7 11641882
9 
11641901
1 
MET 
chr20 57484575 57484634 GNAS-exon9 chr7 11642204
1 
11642215
1 
MET 
chr11 534211 534322 HRAS-exon2 chr7 11642335
7 
11642352
3 
MET 
chr11 533765 533944 HRAS-exon3 chr7 11643570
8 
11643584
5 
MET 
chr2 20911309
2 
20911338
4 
IDH1-exon4 chr7 11643594
0 
11643617
8 
MET 
chr15 90631818 90631979 IDH2-exon4 chr17 7572926 7573008 TP53 
chr4 55564449 55564731 KIT-exon3 chr17 7573926 7574033 TP53 
chr4 55593581 55593708 KIT-exon8 chr17 7576536 7576584 TP53 
chr4 55594176 55594287 KIT-exon11 chr17 7576624 7576657 TP53 
chr4 55595500 55595651 KIT-exon13 chr17 7576852 7576926 TP53 
chr4 55599235 55599358 KIT-exon14 chr17 7577018 7577155 TP53 
chr4 55592024 55592217 KIT-exon15 chr17 7577498 7577608 TP53 
chr4 55597494 55597586 KIT-exon17 chr17 7578176 7578289 TP53 
chr12 25398207 25398318 KRAS-exon2 chr17 7579699 7579721 TP53 
chr12 25380167 25380346 KRAS-exon3 chr17 7579838 7579912 TP53 
chr12 25378547 25378707 KRAS-exon4 chr17 7579311 7579590 TP53 
chr15 66727364 66727575 MAP2K1-exon2 chr17 7578370 7578556 TP53 
chr15 66729083 66729230 MAP2K1-exon3 chr17 7565259 7565332 TP53 
chr15 66774093 66774218 MAP2K1-exon6 chr17 7569526 7569562 TP53 
chr19 4123780 4123872 MAP2K2-exon1 chr2 47630329 47630541 MSH2 
chr19 4117416 4117627 MAP2K2-exon2 chr2 47635538 47635694 MSH2 
chr19 4101016 4101141 MAP2K2-exon6 chr2 47637231 47637511 MSH2 
chr19 4099198 4099412 MAP2K2-exon7 chr2 47639551 47639699 MSH2 
chr2 17809873
2 
17809899
9 
NFE2L2-exon2 chr2 47641406 47641557 MSH2 
chr1 11525866
9 
11525878
1 
NRAS-exon2 chr2 47643433 47643568 MSH2 
chr1 11525641
9 
11525659
9 
NRAS-exon3 chr2 47656879 47657080 MSH2 
chr1 11525218
8 
11525234
9 
NRAS-exon4 chr2 47672685 47672796 MSH2 
chr1 15684619
1 
15684636
4 
NTRK1-exon13 chr2 47690168 47690293 MSH2 
chr1 15684891
3 
15684915
4 
NTRK1-exon14 chr2 47693795 47693947 MSH2 
chr4 55141007 55141140 PDGFRA-exon12 chr2 47698102 47698201 MSH2 
chr4 55144062 55144173 PDGFRA-exon14 chr2 47702162 47702409 MSH2 
chr4 55152007 55152130 PDGFRA-exon18 chr2 47703504 47703710 MSH2 
chr3 17893599
7 
17893612
2 
PIK3CA-exon9 chr2 47705409 47705658 MSH2 
chr3 17895188
1 
17895215
2 
PIK3CA-exon20 chr2 47707833 47708010 MSH2 
chr12 13325313
1 
13325323
9 
POLE-exon9 chr2 47709916 47710088 MSH2 
chr12 13325016
0 
13325029
3 
POLE-exon13 chr2 48010371 48010632 MSH6 
chr12 13324974
9 
13324986
3 
POLE-exon14 chr2 48018064 48018262 MSH6 
chr12 13321999
2 
13322014
6 
POLE-exon34 chr2 48023031 48023202 MSH6 
chr10 89692769 89693008 PTEN-exon5 chr2 48025748 48028294 MSH6 
chr10 89711874 89712016 PTEN-exon6 chr2 48030557 48030824 MSH6 
chr10 89717609 89717776 PTEN-exon7 chr2 48032047 48032166 MSH6 
chr10 89720650 89720875 PTEN-exon8 chr2 48032755 48032846 MSH6 
chr12 11288812
1 
11288831
6 
PTPN11-exon3 chr2 48033341 48033497 MSH6 
chr12 11292682
7 
11292697
9 
PTPN11-exon13 chr2 48033589 48033790 MSH6 
chr10 43595906 43596170 RET-exon2 chr2 48033916 48033999 MSH6 
chr10 43609927 43610184 RET-exon11 chr3 37035037 37035154 MLH1 
chr10 43617393 43617464 RET-exon15 chr3 37038108 37038200 MLH1 
chr10 43615529 43615652 RET-exon16 chr3 37042444 37042544 MLH1 
chr17 56448271 56448394 RNF43-exon2 chr3 37045890 37045965 MLH1 
chr17 56440886 56440961 RNF43-exon3 chr3 37048480 37048554 MLH1 
chr17 56440635 56440767 RNF43-exon4 chr3 37050303 37050396 MLH1 
chr17 56439904 56440009 RNF43-exon5 chr3 37053309 37053353 MLH1 
chr17 56434828 56436184 RNF43-exon8 chr3 37053500 37053590 MLH1 
chr18 48575055 48575230 SMAD4-exon3 chr3 37055921 37056035 MLH1 
chr18 48591792 48591976 SMAD4-exon9 chr3 37058995 37059090 MLH1 
chr18 48593388 48593557 SMAD4-exon10 chr3 37061799 37061954 MLH1 
chr18 48603007 48603146 SMAD4-exon11 chr3 37067126 37067498 MLH1 
chr18 48604625 48604837 SMAD4-exon12 chr3 37070273 37070423 MLH1 
chr7 12884630
4 
12884642
8 
SMO-exon6 chr3 37081675 37081785 MLH1 
chr7 12885020
3 
12885038
9 
SMO-exon9 chr3 37083757 37083822 MLH1 
chr7 12885147
6 
12885161
1 
SMO-exon11 chr3 37089008 37089174 MLH1 
chr20 36031573 36031782 SRC-exon12 chr3 37090006 37090100 MLH1 
chr20 36030838 36030992 SRC-exon14 chr3 37090393 37090508 MLH1 
chr19 1206912 1207202 STK11-exon1 chr3 37091975 37092144 MLH1 
chr19 1220371 1220504 STK11-exon4 chr7 11641170
8 
11641190
2 
MET_intron
13 
chr19 1221211 1221339 STK11-exon6 chr7 11641204
3 
11641214
3 
MET_intron
14 
chr19 1222983 1223171 STK11-exon8 chr5 17477860
3 
17477875
3 
rs251934 
chr5 1294952 1295378 TERT-5-utr chr13 10693833
6 
10693848
6 
rs354439 
chr2 47641426 47641608 Microsatellite_regio
n1 
chr5 2879320 2879470 rs717302 
chr4 55598122 55598274 Microsatellite_regio chr19 28463262 28463412 rs719366 
n2 
chr2 95849306 95849434 Microsatellite_regio
n3 
chr21 16685523 16685673 rs722098 
chr14 23652309 23652419 Microsatellite_regio
n4 
chr6 16504525
9 
16504540
9 
rs727811 
chr11 10219348
5 
10219357
4 
Microsatellite_regio
n5 
chr16 5606122 5606272 rs729172 
chr5 11204341
4 
11204357
9 
APC chr22 27816709 27816859 rs733164 
chr5 11209058
7 
11209072
2 
APC chr10 3374103 3374253 rs735155 
chr5 11210202
2 
11210210
7 
APC chr7 15599073
8 
15599088
8 
rs737681 
chr5 11210288
5 
11210308
7 
APC chr10 2406556 2406706 rs826472 
chr5 11211132
5 
11211143
4 
APC chr14 98845456 98845606 rs873196 
chr5 11211648
6 
11211660
0 
APC chr2 114899 115049 rs876724 
chr5 11212814
2 
11212822
6 
APC chr1 23988185
1 
23988200
1 
rs891700 
chr5 11213697
5 
11213708
0 
APC chr11 11096146 11096296 rs901398 
chr5 11215119
1 
11215129
0 
APC chr2 23956350
4 
23956365
4 
rs907100 
chr5 11215466
2 
11215504
1 
APC chr21 42415854 42416004 rs914165 
chr5 11215759
2 
11215768
8 
APC chr7 4456928 4457078 rs917118 
chr5 11216280
4 
11216294
4 
APC chr10 13269834
4 
13269849
4 
rs964681 
chr5 11216362
5 
11216370
3 
APC chr20 39487035 39487185 rs1005533 
chr5 11216455
2 
11216466
9 
APC chr18 75432311 75432461 rs1024116 
chr5 11217064
7 
11217086
2 
APC chr22 48362215 48362365 rs1028528 
chr5 11217324
9 
11217982
3 
APC chr6 1135864 1136014 rs1029047 
chr7 14043439
6 
14043457
0 
BRAF chr20 4447408 4447558 rs1031825 
chr7 14043961
1 
14043974
6 
BRAF chr13 20901649 20901799 rs1335873 
chr7 14044908
6 
14044921
8 
BRAF chr3 19080603
3 
19080618
3 
rs1355366 
chr7 14045307
4 
14045319
3 
BRAF chr3 961707 961857 rs1357617 
chr7 14045398
6 
14045403
3 
BRAF chr9 12896798
8 
12896813
8 
rs1360288 
chr7 14047671
1 
14047688
8 
BRAF chr16 80106286 80106436 rs1382387 
chr7 14047779
0 
14047787
5 
BRAF chr1 24280672
2 
24280687
2 
rs1413212 
chr7 14048137
5 
14048149
3 
BRAF chr14 25850757 25850907 rs1454361 
chr7 14048282
0 
14048295
7 
BRAF chr9 12688137
3 
12688152
3 
rs1463729 
chr7 14048734
7 
14048738
4 
BRAF chr1 4367248 4367398 rs1490413 
chr7 14049410
7 
14049426
7 
BRAF chr18 1127911 1128061 rs1493232 
chr7 14050016
1 
14050028
1 
BRAF chr15 55210630 55210780 rs1528460 
chr7 14050121
1 
14050136
0 
BRAF chr13 22374625 22374775 rs1886510 
chr7 14050775
9 
14050786
2 
BRAF chr4 19031800
5 
19031815
5 
rs1979255 
chr7 14050869
1 
14050879
5 
BRAF chr15 24571721 24571871 rs2016276 
chr7 14053440
8 
14053467
2 
BRAF chr22 47836337 47836487 rs2040411 
chr7 14054991
0 
14055001
2 
BRAF chr8 13939904
1 
13939919
1 
rs2056277 
chr7 14062436
5 
14062450
3 
BRAF chr11 13466747
1 
13466762
1 
rs2076848 
chr17 37855812 37855840 ERBB2 chr12 888245 888395 rs2107612 
chr17 37856491 37856564 ERBB2 chr12 10632817
9 
10632832
9 
rs2111980 
chr17 37863242 37863394 ERBB2 chr21 28608088 28608238 rs2830795 
chr17 37864573 37864787 ERBB2 chr15 53616834 53616984 rs8037429 
chr17 37865570 37865705 ERBB2 chr1 23843923
3 
23843938
3 
rs10495407 
chr17 37866065 37866134 ERBB2 chrX 1537806 1537956 rs4503285 
chr17 37866338 37866454 ERBB2 chrX 15258478
5 
15258493
5 
rs11453633
1 
chr17 37866592 37866734 ERBB2 chr17 80461859 80462010 rs8078417 
chr17 37868180 37868300 ERBB2 chr17 440422 440572 rs7219151 
chr17 37868574 37868701 ERBB2 chr21 43481545 43481695 rs69686 
chr17 37871538 37871612 ERBB2 chr4 46329580 46329730 rs279844 
chr17 37871698 37871789 ERBB2 chr8 17182466 17182616 rs2239865 
chr17 37871992 37872192 ERBB2 chr9 991039 991189 rs279877 
 
Table S2. NGS custom high depth capture panel. The table lists the regions captured 
by the panel.  
 
